Status:
NOT_YET_RECRUITING
DOTATATE PET for Meningioma Radiation Planning
Lead Sponsor:
British Columbia Cancer Agency
Conditions:
Meningioma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expresse...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Able and willing to comply with the study procedures
- Intact meningioma requiring definitive radiation
- Post-operative meningioma requiring adjuvant radiation
- No prior radiation therapy or medical therapy directed at the tumour
Exclusion
- Breastfeeding or pregnancy
- Claustrophobia or inability to lie still in a supine position
- Unwillingness or inability to provide informed consent
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06937268
Start Date
June 1 2025
End Date
December 31 2027
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Cancer - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6